Compare · TIVC vs TMDX
TIVC vs TMDX
Side-by-side comparison of Tivic Health Systems Inc. (TIVC) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TIVC and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 805.5x TIVC ($4.0M).
- TIVC has been more active in the news (6 items in the past 4 weeks vs 5 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 0 for TIVC).
- Company
- Tivic Health Systems Inc.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $4.0M
- $3.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 6
- 5
- Recent ratings
- 0
- 19
Tivic Health Systems Inc.
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. The company's primary product, ClearUP, is a medical device intended to relieve sinus and nasal inflammation. It sells its products on direct-to-consumer channel through its own websites and platforms, such as Amazon.com, as well as to major U.S. online retailers, such as BestBuy.com, FSAStore.com, Walgreens.com, Walmart.com. The company was incorporated in 2016 and is headquartered in Newark, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest TIVC
- SEC Form RW filed by Tivic Health Systems Inc.
- Amendment: Tivic Health Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Tivic Health Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Tivic Health Systems Inc.
- SEC Form EFFECT filed by Tivic Health Systems Inc.
- Tivic Health Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Unregistered Sales of Equity Securities
- SEC Form DEF 14A filed by Tivic Health Systems Inc.
- SEC Form S-1 filed by Tivic Health Systems Inc.
- Tivic Health Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form PRE 14A filed by Tivic Health Systems Inc.
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)